Anzeige
Meldung des Tages: Auftakt zu Maßnahmen: Grundlegendes Material für die Verteidigungsindustrie der USA wird immer wichtiger

Novo-Nordisk Aktie (ADR) News

Aktie
WKN:  866931 ISIN:  US6701002056 US-Symbol:  NVO Branche:  Pharmazeutika Land:  Dänemark
58,61 $
-0,82 $
-1,38%
49,694 € 16:36:14 Uhr
Depot/Watchlist
Marktkapitalisierung *
150,01 Mrd. €
Streubesitz
89,76%
KGV
27,28
Dividende
1,68 $
Dividendenrendite
3,87%
Faktor
1
Originalaktie
DK0062498333
Weiter abwärts? Short handeln - Jetzt mit Hebel 6,15: UQ0JXP
Werbung

Novo-Nordisk Aktie (ADR) News

05.01.26 - PR Newswire
Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America
Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America PR Newswire
31.12.25 - PR Newswire
The End of Shots? 5 Biotech Stocks Rethinking Diabetes
The End of Shots? 5 Biotech Stocks Rethinking Diabetes PR Newswire
23.12.25 - ARIVA.DE Redaktion
Novo Nordisk: Das verändert alles!
Der dänische Pharma- und Biotechkonzern hat eine Zulassung für sein oral verabreichtes GLP-1-Präparat erhalten. Die Aktie macht einen Riesensatz nach oben.
06.11.25 - PR Newswire
Novo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek®
Novo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-​inflammatory effects while reducing the proportion of patients at risk of ...
06.11.25 - PR Newswire
Novo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek®
Novo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-​inflammatory effects while reducing the proportion of patients at risk of ...
20.10.25 - ARIVA.DE Redaktion
Novo Nordisk: Auf schlechte folgen bereits wieder gute Nachrichten! Platzt jetzt der Knoten?
Nachdem die Aktie des dänischen Pharmakonzerns in der vergangenen Woche noch unter die Räder gekommen war, legt sie am Montag einen starken Auftakt hin.
06.10.25 - inv3st.de
Novo Nordisk, Fuelcell Energy und Almonty Industries mit starkem Rebound
Während nicht wenige Analysten aufgrund der hohen Bewertungen an den Weltbörsen, der Warren Buffett-​Indikator steht beispielhaft auf einem historischen Höchststand und ...
01.10.25 - PR Newswire
Class Action Filed Against Novo Nordisk A/S (NVO) Seeking Recovery for Investors - Contact Levi & Korsinsky
Class Action Filed Against Novo Nordisk A/S (NVO) Seeking Recovery for Investors - Contact Levi & Korsinsky PR Newswire
30.09.25 - PR Newswire
NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm
NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
30.09.25 - LYNX Analysen
Novo Nordisk: Die Bullen verlieren den Anschluss
Die Novo-​Nordisk-Aktie hat nach einem vielversprechenden Rebound an Schwung verloren. Ist die mögliche Trendwende schon wieder gefährdet? Jetzt vollständige Analyse lesen
29.09.25 - PR Newswire
NVO Deadline: NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
NVO Deadline: NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit PR Newswire
29.09.25 - ARIVA.DE Redaktion
Novo Nordisk: Deshalb ist die Aktie schon wieder im Rückwärtsgang!
Die Anteile des dänischen Pharmakonzerns Novo Nordisk erwischen einen schwachen Wochenauftakt. Eine Verkaufsempfehlung und technische Schwäche belasten die Aktie.
29.09.25 - PR Newswire
Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - NVO
Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - NVO PR Newswire
28.09.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO PR ...
26.09.25 - PR Newswire
Novo Nordisk A/S (NVO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Novo Nordisk A/S (NVO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire
26.09.25 - PR Newswire
Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 30, 2025 to Discuss Your Rights - NVO
Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 30, 2025 to Discuss Your Rights - NVO PR Newswire
26.09.25 - PR Newswire
CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Novo Nordisk A/S (NYSE: NVO) Investors to Inquire About a Securities Fraud Class Action by September 30, 2025
CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Novo Nordisk A/S (NYSE: NVO) Investors to Inquire About a Securities Fraud Class Action by September 30, ...
25.09.25 - PR Newswire
The Gross Law Firm Notifies Shareholders of Novo Nordisk A/S(NVO) of a Class Action Lawsuit and an Upcoming Deadline
The Gross Law Firm Notifies Shareholders of Novo Nordisk A/S(NVO) of a Class Action Lawsuit and an Upcoming Deadline PR Newswire
24.09.25 - PR Newswire
Novo Nordisk A/S (NVO) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Novo Nordisk A/S (NVO) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire
24.09.25 - PR Newswire
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk PR Newswire

Newssuche

Videos

newspaper
12:40 Uhr +1,63%
Technical Trading Silber Crash!
Silber Short Typ: Turbo Open End WKN: VJ4GQU Hebel: 3,77 Laufzeit: OpenEnd Einstieg: Market ... Mehr »